EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Understanding medical cannabis use internationally: Why definitions and context matter

Myfanwy Graham iD, Rosalie Liccardo Pacula iD, Seema Choksy Pessar iD, Yimin Ge, Alexandra F Kritikos, Wayne Hall iD, David Hammond iD

Addiction · 2025

DOI: 10.1111/add.70117 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Addiction, 2025. Verfasst von Myfanwy Graham und 6 weiteren Autor:innen. Beteiligte Einrichtung: Monash Addiction Research Centre, Monash University, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Medical Marijuana, Marijuana Use. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Canadian Institutes of Health Research (CIHR), Institute of Population and Public Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To identify variation in identification of medical consumers using alternative self‐reported measures and assess whether differences in these rates exist across jurisdictions with different medical policy approaches using evidence from an international study on cannabis use.

Design

Secondary analysis of wave 4 (2021) of the International Cannabis Policy Study (ICPS) cross‐sectional survey.

Setting

United States, Canada and Australia.

Participants

16 951 (USA 10 472; CAN 5935; AUS 544) respondents who completed the survey and reported past year cannabis use across the three jurisdictions.

Measurements

Four different medical cannabis use measures were available, and rates of each were estimated using logistic regression methods that adjusted for age, gender, education and ethnicity. Medical cannabis use measures included potentially authorized use (i.e. involving a licensed health professional recommendation, authorization or prescription), pharmaceutical use (i.e. involving a pharmaceutical‐grade product), therapeutic use (i.e. to manage physical or mental health conditions) and self‐identified medical cannabis use. Country‐specific differences were compared and discussed in light of measure and differing cannabis policies.

Findings

In wave 4 of the ICPS, 34.0% reported any past year cannabis use, but rates of medical use differed significantly according to the specific question. Far more individuals reported therapeutic use in the past year across all countries [77.3%; 95% confidence interval (CI) = 76.4%–78.2%] than any other measure of medical use. While just over one quarter (28.2%; 95% CI = 27.3%–29.2%) self‐identified as a medical user, fewer reported being potentially authorized (22.8%; 95% CI = 22.0%–23.7%) or having a pharmaceutical prescription from a medical professional (12.3%; 95% CI = 11.6%–13.0%). Australians (27.2%; 95% CI = 23.0%–31.4%) and Americans (25.9%; 95% CI = 24.6%–27.2%) were more likely to report potentially authorized use than Canadians (17.3%; 95% CI = 16.1%–18.4%), but only Australians (27.4%; 95% CI = 23.6%–31.2%) reported high levels of prior use of a pharmaceutical‐grade cannabinoid.

Conclusions

In the International Cannabis Policy Study, the proportion of respondents (adjusted for demographic factors) who reported medical use varied depending on the measures used within and between countries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Medical MarijuanaMarijuana UseHumansMaleFemaleAustraliaAdultUnited StatesCross-Sectional StudiesCanadaYoung AdultMiddle AgedAdolescentSelf Report

Stichwörter der Autor:innen

cannabis policymedical cannabismethodologypublic healthrecreational cannabissurveys and questionnaires

Substanzen

Medical Marijuana

Autor:innen und Institutionen

  • Monash Addiction Research Centre, Monash University, Melbourne, VIC, Australia.
  • Centre for Drug Repurposing and Medicines Research, Hunter Medical Research Institute, Newcastle, NSW, Australia.
  • Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, CA, USA.
  • Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
  • NORC, University of Chicago, Cambridge, MA, USA.
  • Centre for Youth Substance Abuse Research, University of Queensland, Brisbane, QLD, Australia.

ORCID-Profile: Myfanwy Graham, Rosalie Liccardo Pacula, Seema Choksy Pessar, Wayne Hall, David Hammond

Förderung

  • National Health and Medical Research Council
  • Canadian Institutes of Health Research (CIHR)
  • Institute of Population and Public Health

Zitieren

APA

Graham, M., Pacula, R. L., Pessar, S. C., Ge, Y., Kritikos, A. F., Hall, W., & Hammond, D. (2025). Understanding medical cannabis use internationally: Why definitions and context matter. Addiction. https://doi.org/10.1111/add.70117

Vancouver

Graham M, Pacula RL, Pessar SC, Ge Y, Kritikos AF, Hall W, et al. Understanding medical cannabis use internationally: Why definitions and context matter. Addiction. 2025. doi:10.1111/add.70117

BibTeX
@article{Graham2025,
  author = {Graham, Myfanwy and Pacula, Rosalie Liccardo and Pessar, Seema Choksy and Ge, Yimin and Kritikos, Alexandra F and Hall, Wayne and Hammond, David},
  title = {Understanding medical cannabis use internationally: Why definitions and context matter},
  journal = {Addiction},
  year = {2025},
  doi = {10.1111/add.70117}
}
Kostenlos starten →